2-[4-amino-4-[5-fluoro-6-(2-methoxyphenyl)-3-pyridinyl]piperidin-1-yl]-5-(trifluoromethyl)benzonitrile
C25H22F4N4O — CID 156502293
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[4-amino-4-[5-fluoro-6-(2-methoxyphenyl)-3-pyridinyl]piperidin-1-yl]-5-(trifluoromethyl)benzonitrile
2-[4-amino-4-[5-fluoro-6-(2-methoxyphenyl)-3-pyridinyl]piperidin-1-yl]-5-(trifluoromethyl)benzonitrile (PubChem CID 156502293) has the molecular formula C25H22F4N4O and a molecular weight of 470.47 g/mol. Its IUPAC name is 2-[4-amino-4-[5-fluoro-6-(2-methoxyphenyl)-3-pyridinyl]piperidin-1-yl]-5-(trifluoromethyl)benzonitrile.
Molecular Properties
| Compound Name | 2-[4-amino-4-[5-fluoro-6-(2-methoxyphenyl)-3-pyridinyl]piperidin-1-yl]-5-(trifluoromethyl)benzonitrile |
|---|---|
| PubChem CID | 156502293 |
| Molecular Formula | C25H22F4N4O |
| Molecular Weight | 470.47 g/mol |
| Exact Mass | 470.17 |
| IUPAC Name | 2-[4-amino-4-[5-fluoro-6-(2-methoxyphenyl)-3-pyridinyl]piperidin-1-yl]-5-(trifluoromethyl)benzonitrile |
| SMILES | COc1ccccc1-c1ncc(C2(N)CCN(c3ccc(C(F)(F)F)cc3C#N)CC2)cc1F |
| InChI | InChI=1S/C25H22F4N4O/c1-34-22-5-3-2-4-19(22)23-20(26)13-18(15-32-23)24(31)8-10-33(11-9-24)21-7-6-17(25(27,28)29)12-16(21)14-30/h2-7,12-13,15H,8-11,31H2,1H3 |
| InChIKey | DLEBVBLVJAYENO-UHFFFAOYSA-N |
| XLogP | 5.24 |
| TPSA | 75.17 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 470.47 |
| LogP ≤ 5 | 5.24 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156502293 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.